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Abstract:  
Rheumatoid arthritis (RA) is a debilitating disease characterised by persistent 
accumulation of leukocytes within the articular cavity and synovial tissue. 
Metabololipidomic profiling of arthritic joints from omega-3 supplemented mice 
identified elevated levels of specialized pro-resolving lipid mediators (SPM) including 
resolvin D1 (RvD1). Profiling of human RA synovial fluid revealed physiological 
levels of RvD1, which once applied to human neutrophils attenuated chemotaxis. 
These results prompted analyses of the anti-arthritic properties of RvD1 in a model of 
murine inflammatory arthritis. The stable epimer 17R-RvD1 (100ng/day) significantly 
attenuated arthritis severity, cachexia, hind-paw edema, paw leukocyte infiltration and 
shortened the remission interval. Metabololipidomic profiling in arthritic joints 
revealed 17R-RvD1 significantly reduced PGE2 biosynthesis, whilst increasing levels 
of protective SPM. Molecular analyses indicated that 17R-RvD1 enhanced expression 
of genes associated with cartilage matrix synthesis, and direct intra-articular treatment 
induced chondroprotection. Joint protective actions of 17R-RvD1 were abolished in 
RvD1 receptor deficient mice termed ALX/fpr2/3-/-. These investigations open new 
therapeutic avenues for inflammatory joint diseases providing mechanistic substance 
for the benefits of omega-3 supplementation in RA. 
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Introduction: 
Rheumatoid arthritis (RA) is a chronic debilitating disease characterised by persistent 
synovitis, which leads to joint damage, increased disability and accelerated 
cardiovascular disease, and hence higher mortality (1). It is now appreciated that 
chronic inflammatory diseases such as arthritis may persist due to a failure of 
resolution responses (2). Current treatment strategies for RA aim to intervene early to 
consistently limit inflammation in order to maintain joint integrity (3). Accordingly, 
patient prognosis has dramatically improved since earlier diagnosis, along with the 
revolutionary advent of biologics, and treatment with disease modifying anti-
rheumatics and methotrexate (4). Despite this, current expectations are that only 50% 
of treated patients will exhibit a reduction in disease activity score from high to a 
sustained level of low or, more rarely, remission (4). In addition treatment controls yet 
seldom repairs joint damage (5) and patients on therapies with biologics develop an 
increased risk of opportunistic infections (4, 6). Thus new therapeutic approaches that 
can counter disease chronicity and maintain joint integrity are required.  
 
In order to circumvent the progress of acute self-resolving to persistent-chronic 
inflammation, the inflammatory response must be actively resolved. It is now 
appreciated that this process is not passive as once believed but governed by the 
spatiotemporal production of endogenous pro-resolving mediators for recent review 
see ref. (2). Uncovering these mediators, and elucidating their mechanisms of action 
has shed light on the promising nature of these compounds as potential therapeutics 
(7). Omega-3 PUFA, which are abundant in marine oils, are precursors to a new 
genus of bioactive lipid mediators that comprise the lipoxins, resolvins, protectins and 
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maresins (collectively termed specialised pro-resolving lipid mediators (SPM) (2, 7)), 
which exhibit potent and stereoselective protective properties such as limiting further 
neutrophil recruitment, enhancing containment and clearance of infections, and 
reducing inflammatory pain (2, 7, 8). Dietary supplementation with fish oils has 
proved efficacious in reducing joint pain, swollen joint count and NSAID usage in RA 
patients, yet there is an unmet need to determine the mechanism of action(s) of these 
supplements (9, 10). Thus SPM may offer a molecular mechanism and basis for the 
beneficial effects of omega-3 consumption in specific RA clinical endpoints (9, 10).  
 
In the present study, we performed lipid mediator metabololipidomics on arthritic 
joints from mice fed a standard versus an omega-3 enriched chow to directly compare 
the local bioactive lipid mediator metabolome. Amongst the mediators quantified, we 
identified elevated levels of RvD1; that was also identified in human RA synovial 
fluids. When its 17R epimer (selected for its increased metabolic stability (11)) was 
administered to mice during inflammatory arthritis it significantly reduced joint 
inflammation. Herein, we report novel mechanisms of action of RvD1 and tested its 
anti-arthritic potential in an inflammatory polyarthritis model evoked by transfer of 
arthritogenic serum that mimics the presentation and histopathology of human RA.  
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Results: 
Dietary supplementation with omega-3 PUFA reduces arthritis and modulates the 
local lipid mediator profile. We tested whether a fish oil enriched diet could modulate 
the local bioactive lipid mediator metabolome and assessed the functional 
consequences of regulating tissue levels of these potent mediators in a neutrophillic 
model of arthritis triggered by transfer of arthritogenic serum (12). This model of 
arthritis is dependent upon IgG, FcγRs, complement, LTB4 and IL-1β and is not 
dependent upon the adaptive immune system, yet requires a variety of innate immune 
cells including mast cells, macrophages and neutrophils allowing the study of the 
innate immune system in arthritis (12). Mice fed an omega-3 enriched chow exhibited 
a reduced arthritic score as compared to those on a standard chow diet (Figure 1A). 
We next performed lipid mediator metabololipidomics on arthritic paws. Mediators 
from the arachidonic acid (AA), eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA) bioactive metabolomes were identified and quantified in murine paws in 
accordance with published criteria including matching retention times on liquid 
chromatography (LC) and tandem mass spectrometry (MS/MS) fragmentation spectra 
(13) (Table 1).  
 
Distinct profiles of lipid mediators were identified in naïve, arthritic and omega-3 
supplemented mice undergoing arthritis, which could be separated utilising linear 
discriminant analysis (Figure 1B). Thus, correlations between individual lipid 
mediators and the three treatment groups were plotted (Figure 1C). Higher levels of 
maresin (MaR) 1 were found in naïve as compared to arthritic paws. Comparatively, 
arthritic joints were associated with higher levels of pro-inflammatory prostanoids 
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including thromboxane (TX) B2, prostaglandin (PG) D2, PGE2 and PGF2α as well as 
leukotriene (LT) B4. Whereas the paws of arthritic mice supplemented with an 
omega-3 enriched diet were characterised by elevated levels of specialised pro-
resolving lipid mediators (SPM) including EPA derived resolvin (Rv) E2 and RvE3 
and DHA derived resolvins, of which RvD1 and RvD5 were significantly increased 
(Table 1, Fig 1C). These findings suggest that local production of SPM within the 
joints of omega-3 supplemented mice may contribute to the reduction in arthritis 
severity. 
 
Identification of SPM in human RA synovial fluids. We next profiled synovial fluid 
from human RA patients to determine the bioactive lipid mediator metabolome found 
within human joints (refer to Table 2 for patient demographics/treatment regimes). 
Using LC-MS/MS-based lipid mediator metabololipidomics we identified mediators 
from all three major bioactive metabolomes in human synovial fluids including DHA-
derived resolvins and AA-derived eicosanoids (Figure 2A). Similarly to murine 
arthritic joints, AA-derived autacoids classically associated with joint pain and 
inflammation were detected within the synovial effusate, including PGE2, PGD2, 
PGF2α, TXB2 and LTB4. In these fluids we also identified the pathway marker for the 
protective lipoxin family 5,15-diHETE as well as the D-series resolvins, RvD1 and 
RvD3. All of these mediators were all identified in accordance with published criteria 
including matching retention times in LC (Figure 2A) and characteristic/diagnostic 
MS-MS fragmentation patterns (Figure 2B). Of note, the levels of these pro-resolving 
mediators in these inflammatory exudates were detected within physiologically 
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relevant concentrations (RvD1, ∼31pM, bioactive concentrations: 10pM-100nM; 
RvD3, ∼23pM bioactive concentrations 1pM-10nM) (8, 14, 15) (Table 3). 
 
Pro-resolving lipid mediators directly impact neutrophil migration. As arthritic 
synovial exudates contain abundant neutrophils, we utilized microfluidics chambers 
that provide defined spatiotemporal concentration gradients to study the role of SPM 
in regulating neutrophil chemotaxis in real-time and at a single cell level. We directly 
compared the actions of LXA4, LXB4, RvD1 or RvD2 on neutrophil migration 
towards IL-8, a classical neutrophil chemotaxis signal. Initially neutrophils were 
exposed to IL-8 (10nM) alone, then exposed to a set concentration (1nM) of SPM 
concomitantly with the IL-8 gradient over the subsequent 15 min. In the absence of 
IL-8 superfusion any captured PMN remained rounded and rapidly detached during 
the first minute of flow (Figure S1A, still images), this was also the case following 
exposure to SPM alone (data not shown).  
 
Displacement and directionality were determined for each individual cell by tracking 
the cell centroid utilizing ImageJ software analysis. Following exposure to IL-8, cells 
migrated in the direction of the chemotactic gradient as seen by vertical cell trajectory 
paths (Figure 3A; veh), with general direction depicted by the rose plot (Figure 3B; 
veh). Inset in Figure 3B shows the polarized morphology of neutrophils after 
exposure to IL-8 plus vehicle (0.1% ethanol). In the presence of LXA4, RvD1 or 
RvD2 neutrophils no longer responded to the chemotactic signal, and instead migrated 
in the direction of fluid flow (Figure 3A, B). Whilst with 1nM LXB4, cells still 
responded to IL-8 and retained their polarized morphology. Rose plots for each 
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individual donor were plotted separately (Figure S1B-F). The chemotaxis index was 
calculated for each SPM as graphically illustrated in Figure 3C. LXA4, RvD1 and 
RvD2 all significantly blunted PMN chemotaxis by approximately 75%. The 
directionality of neutrophil migration was also calculated for each SPM (see 
illustration Fig 3D); exposure to LXA4 or RvD2 significantly reduced direct travel i.e. 
increased random movement. These results demonstrate that at low nanomolar 
concentrations, LXA4, RvD1 and RvD2 each selectively impact and reduce 
directional migration towards IL-8. We subsequently selected RvD1, which 
significantly attenuated PMN chemotaxis yet had little effect on random migration to 
test in a neutrophilic model of arthritis. 
 
Treatment of mice with 17R-RvD1 treatment confers protection from inflammatory 
arthritis. RA is a progressive inflammatory disease characterized by extensive 
infiltration of leukocytes into the synovial cavity and articular tissues. Given that 
RvD1 significantly regulated human neutrophil responses and its 17R-epimer retains 
the bioactions of RvD1 while displaying higher metabolic stability (11) we next 
investigated the therapeutic potential of 17R-RvD1 (7S,8R,17R-trihydroxy-
4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid) in protecting against leukocyte 
mediated join damage. Mice were injected with arthritogenic K/BxN serum and 
monitored over 8 days. Administration of K/BxN serum triggered robust arthritis, 
which rapidly developed over the first few days (Figure 4A). 17R-RvD1 treated mice 
exhibited a lower clinical score, and reduced hind paw edema compared with vehicle 
treated mice (Figure 4A and B). 17R-RvD1 also protected from the transient weight 
loss associated with arthritis (Figure 4C). Disease penetrance, defined as the 
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proportion of mice developing a clinical score greater than 1 out of a maximum 12 
was 100% regardless of treatment group (Figure 4D), yet the clinical data indicates 
17R-RvD1 significantly reduced disease severity.  
 
In addition to the macroscopic assessment of arthritis, histological analyses were 
performed on knee joints to assess inflammatory infiltrate, cartilage degradation, and 
evidence of bone erosion. Microscopic analyses of the naïve, non-arthritic articular 
joint presented little evidence for leukocyte infiltration and demonstrated intact 
cartilage and bone. Arthritic serum provoked a marked accumulation of leukocytes 
within the joint as well as evident pannus formation and synovial hypertrophy as 
compared with naïve animals, whereas 17R-RvD1 treatment limited leukocyte 
recruitment, synovitis and pannus intrusion (Figure 4E-G, Figure S2A,B). Blinded 
analyses of histopathological sections revealed a significant tissue protection by 17R-
RvD1 (Figure 4H). Levels of KC (CXCL1), a key chemokine known to drive 
inflammatory arthritis and promote leukocyte recruitment, were assessed (16). Plasma 
levels were elevated during arthritis and were significantly dampened following 17R-
RvD1 treatment (Figure 4I). Further studies were performed to decipher which 
leukocytes infiltrated arthritic joints. Flow cytometric analyses identified neutrophil 
(Ly6GhiCD11bhi), monocyte (Ly6ChiLy6Glo) and macrophage (F4/80hiLy6Glo) 
accumulation within arthritic paws. Each of these leukocyte subtypes was 
significantly reduced in paws from 17R-RvD1 treated mice (Figure 4J-L).  
 
Current arthritis treatment strategies aim to intervene early to reduce synovitis and 
prevent cartilage degradation and bone erosion (3). Hence, our interest was to 
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determine whether 17R-RvD1 would be effective at reducing the clinical signs of 
early experimental arthritis. Therapeutic administration of resolvins at the peak of an 
acute inflammatory response is known to accelerate the resolution process (17). 
Therefore the time taken to remit (remission interval) based on clinical score was 
calculated analogously to the resolution interval widely used to calculate the loss of 
neutrophils from an inflammatory site by 50% (17, 18). 17R-RvD1 was tested as a 
therapeutic agent after the second dosing of K/BxN serum when mice exhibited overt 
signs of arthritis (100ng, i.p. daily from day 4-10). Resolvin treatment limited the 
arthritis severity (Tmax; Veh day 8, max. score 9.5 vs. 17R-RvD1 day 6, max. score 7) 
and shortened the remission interval (Ri: Veh 15 days, 17R-RvD1 9 days) (Figure 
4M). This experiment demonstrates the potential of 17R-RvD1 as a therapeutic for 
limiting tissue damage in patients with early RA.   
 
Administration of 17R-RvD1 selectively modulates the local bioactive lipid 
metabolome within arthritic paws. Because RvD1 regulates pro-inflammatory 
eicosanoid biosynthesis during acute peritonitis (15), we next performed lipid 
mediator metabololipidomics on arthritic paws obtained 8 days after K/BxN serum 
administration to elucidate the potential mechanism(s) underlying 17R-RvD1 actions. 
Identification was conducted using established criteria (13), including liquid 
chromatography (LC) retention time and at least 6 fragment diagnostic ions in the 
MS/MS as illustrated for LTB4 and PGE2 (Figure 5A&B). In these paws, mediators 
from each of the three major bioactive metabolomes were identified including the 
following eicosanoids: LTB4, LXA4 and LXB4 from the lipoxygenase pathway and 
PGE2, PGD2, PGF2α and TXB2 from the cyclooxygenase pathways (Figure 5C). 
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Multiple reaction monitoring (MRM) was utilised to quantify the individual mediator 
amounts. We found that 17R-RvD1 down-regulated production of pro-inflammatory 
LTB4; an essential mediator required for the development of experimental arthritis 
(19) along with TXB2 and prostaglandins E2, PGD2 and PGF2α whilst activating 
protective LXA4 and LXB4 biosynthesis (Figure 5C). We also found that 17R-RvD1 
stimulated the biosynthesis of EPA-derived SPM including the E-series resolvins 
RvE2 and RvE3 by ~50%. From the DHA bioactive metabolome PDx was 
significantly elevated in mice treated with 17R-RvD1. Thus, this exquisite regulation 
of lipid mediators may contribute to the joint protective actions following 
pharmacological delivery of 17R-RvD1.  
 
Gene expression analysis was performed on paw tissue from arthritic mice treated 
with vehicle and 17R-RvD1 observing selective modulatory functions. A trend for 
down-modulation of Il1b, the key cytokine driving K/BxN arthritis, Ly6g, a marker of 
neutrophil influx, and Ptsg2 (cyclooxygenase-2) essential for prostaglandin 
biosynthesis was detected in mice given 17R-RvD1. On the other hand, higher 
expression of Alox15 (15-lipoxygenase) transcript, a key gene in SPM biosynthesis 
was detected in mice treated with 17R-RvD1 (Table S1). Most notably, a significant 
up-regulation of key genes involved in cartilage matrix synthesis was observed, 
namely type II collagen and aggrecan (Figure 6A). This unpredicted finding brought 
us to investigate the impact of 17R-RvD1 treatments on cartilage erosion during 
K/BxN arthritis. After the onset of arthritis (day 3), mice were administered 17R-
RvD1 (100ng) directly into the knee joint along with PBS (+0.1% ethanol) into 
contralateral knees as control, with histological analyses being performed on day 5. 
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Cartilage integrity was first assessed in naïve mice, whereby the cartilage remained 
intact regardless of PBS or 17R-RvD1 treatment as measured by toluidine blue 
staining (Figure 6B, left panels and Figure 6C analyses). Whereas a marked reduction 
in toluidine blue staining on the cartilage surface was observed in PBS-injected knees 
of arthritic mice indicating loss of glycosaminoglycans (Figure 6B, upper right panel, 
white arrowheads). Remarkably, a significant protection from cartilage damage was 
evident in 17R-RvD1 treated joints as compared to paired contralateral control knees 
(Figure 6B, lower right panel and Figure 6C analyses).  
 
To determine whether this was a direct effect on the chondrocytes rather than an 
indirect reduction of leukocyte/stromal cell-induced cartilage degradation, we took 
advantage of the human chondrocyte (C28/I2) micromass system to evaluate 
extracellular matrix (ECM) accumulation (20). Treatment of micromasses with 17R-
RvD1 (0.1-100nM) resulted in a slight but non-significant increase in ECM 
accumulation (Figure 6D). When chondrocytes were stimulated with IL-1β a 
characteristic loss in ECM was quantified. Of note, 17R-RvD1 treatments 
significantly protected against the catabolic effects of concomitant IL-1β stimulation, 
leading to increased extracellular matrix deposition (Figure 6D and representative 
images of Alcian blue stained micromasses). As chondrocytes express the 17R-RvD1 
receptor ALX/FPR2 (21) and 17R-RvD1 demonstrated direct actions on 
chondrocytes, we sought to determine whether this was via receptor ligation of 
ALX/FPR2. Addition of the specific antagonist WRW4 did not have any effect on 
resting or IL-1β treated micromasses alone. However, the accumulative effects of 
17R-RvD1 were reversed by the addition of WRW4, suggesting this protective effect 
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was mediated via ALX/FPR2 (Figure 6E). Further support of ALX/FPR2 receptor 
dependency for the protective actions of 17R-RvD1 was attained in vivo by utilising 
mice nullified with the orthologue receptor Fpr2/3 (22). Accordingly, we subjected 
these mice to arthritis and treated them daily with either vehicle (PBS + 0.1% EtOH, 
i.p.) or 17R-RvD1 (100ng, i.p.). In the absence of Fpr2/3, 17R-RvD1 no longer 
attenuated the clinical score (Figure 6F), swelling of hind paws or the arthritis-related 
manifestation of cachexia, and disease penetrance was almost identical between the 
two genotypes (data not shown). Histopathology of murine hind paws indicated 
substantial leukocyte infiltration (Fig S3A), with near maximal score (3/3) for both 
genotypes (Figure S3B). In summary, joint protection afforded by 17R-RvD1 was 
abolished in the absence of ALX/Fpr2/3.  
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Discussion: 
RA is a chronic progressive autoimmune disease characterized by inflammation of the 
joints that manifests as swelling, pain and functional impairment. This condition can 
also lead to muscle wasting and osteoporosis and is associated with systemic 
inflammatory co-morbidities such as periodontitis and cardiovascular disease (1, 23). 
Although current therapeutics have revolutionized the management of RA, existing 
treatments aimed at limiting joint inflammation are associated with unwanted side-
effects including GI disturbances and increase risk of infections. In addition, although 
current therapeutics may lead to significant improvement in patient prognosis by 
slowing or stopping disease progression, treatment rarely repairs joint damage (5).  
 
We report here an elevated local production of SPM in arthritic joints from mice 
supplemented with an omega-3 enriched chow, a biochemical response that correlates 
with a reduction in arthritis severity. Using targeted lipid mediator 
metabololipidomics, we identified RvD1 as an SPM that was both elevated in arthritic 
paws from omega-3 supplemented mice and present in human RA synovial fluids, 
detected within the concentration range for physiological activities. Thus, when we 
tested the stable epimer 17R-RvD1 (11), a selective modulation of local lipid mediator 
biosynthesis and reduction in joint leukocyte infiltration was observed paralleled by 
macroscopic amelioration of arthritis severity, cachexia and hind-paw edema. We also 
uncovered novel tissue-protective functions of 17R-RvD1, such as stimulation of 
chondrocyte matrix production and protection from cartilage degradation. Together 
these findings identify 17R-RvD1 as a prototype for new therapeutic approaches for 
the treatment of arthritis. 
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Timely resolution of an inflammatory response is pertinent to maintain tissue 
homeostasis. To date, we and others have identified a number of endogenous 
mediators that activate resolution pathways to actively switch off inflammation, 
including annexin-A1 (24), gaseous mediators (e.g. hydrogen sulphide (25) and 
carbon monoxide (26, 27)) as well as specialised pro-resolving lipid mediators (SPM; 
lipoxins, resolvins, protectins and maresins (2, 7)). Dysregulated inflammation is a 
common determinant of many pathologies, yet only recently it was appreciated that 
diseases such as RA may persist, at least in part, due to a failure of resolution (28). 
Accordingly, essential protective roles for endogenous SPM and their receptors are 
indicated in experimental arthritis. Null mice lacking either 12/15-LOX (a key 
enzyme involved in SPM biosynthesis) or ALX/FPR2 (a high-affinity receptor for 
RvD1, LXA4 and annexin A1), display exacerbated disease severity and tissue damage 
in inflammatory arthritis (29, 30). Additionally, mice nullified for 5-LOX (another 
key enzyme involved in SPM biosynthesis) exhibit intensified and prolonged duration 
of infectious arthritis (31). Furthermore, inhibiting COX-2 activity delays the 
resolution of collagen-induced arthritis, which can be restored with PGE2-mediated 
LXA4 production (32). Together, results from these studies emphasize the importance 
of endogenous SPM for the control of arthritis. Early studies demonstrated the 
protective effects of supplementing mice with fish oil enriched diet, with reduced 
susceptibility and lower severity scores when subjected to collagen-induced arthritis 
(33, 34). Congruently, we found that arthritic mice fed a fish oil enriched diet 
displayed attenuated arthritis that was associated with a reduction in pro-inflammatory 
lipid mediator levels and an enhanced biosynthesis of omega-3-derived SPM.   
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Enzymes of the SPM biosynthetic pathway as well as the RvD1 receptor are 
expressed in the rheumatoid synovium. Compared to OA synovia, elevated levels of 
5- and 15-LOX as well as ALX/FPR2 are detected in synovial tissue of RA patients 
(35, 36). In the present study, we identified both RvD1 and RvD3 along with the 
lipoxin pathway marker 5,15-diHETE in synovial fluids from RA patients. These 
results add to the recent identification of RvD5, MaR1 and LXA4 within synovial 
fluid (37). From these findings, we propose that metabololipidomic profiling can 
assist in RA patient stratification with the definition of lipid mediator profiles 
associated with specific cohorts and in the assignment of precision medical treatments 
and personalized RA patient care. 
 
Aberrant infiltration of immune cells into the joint and the subsequent destruction of 
bone and cartilage drive loss of function. During active phases of RA, neutrophils 
present within synovial fluids contribute to disease pathogenesis via release of 
cytotoxic enzymes and reactive oxygen species (38). We previously reported that 
RvD1 (0.1-100nM) significantly dampened neutrophil recruitment to TNF-α 
stimulated endothelium (39), a pivotal cytokine that drives RA (6). Using 
microfluidics chambers to study bioactions at the single cell level under flow of 
continuous chemokine gradients, we observed potent actions of RvD1 at low 
nanomolar concentrations, blunting directed neutrophil locomotion. Thus, we utilized 
the K/BxN serum transfer model of arthritis to test the efficacy of the stable epimer 
17R-RvD1. In this model of symmetric polyarthritis, daily treatment with 17R-RvD1 
preserved joint integrity and lessened the histopathology of arthritis, with reduced 
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synovitis and pannus intrusion, and overall leukocyte infiltration. We previously 
demonstrated that 17R-RvD1 enriched nanoparticles limit leukocyte recruitment into 
the inflamed temporomandibular joint (40). Our current results emphasize the 
protective actions of 17R-RvD1 in limiting joint inflammation.  
 
It is known that a lipid-cytokine-chemokine cascade drives neutrophil recruitment 
during experimental arthritis (16). Mechanistically, we found that administration of 
17R-RvD1 down-regulated Ptsg2 and elevated Alox15 gene expression resulting in 
the selective modulation of the local lipid mediator metabolome. We measured 
reduced LTB4 and prostaglandin levels that contribute to the pain and perpetuation of 
joint inflammation and identified select regulation of SPM levels that may contribute 
to the protective effects afforded by 17R-RvD1 administration. We also determined 
that 17R-RvD1 reduced systemic KC (CXCL1) levels, a principal chemokine that 
recruits neutrophils, and down-regulated Il1b transcripts, a key cytokine that amplifies 
arthritis. The main cellular source of this cytokine in this experimental model of 
arthritis is neutrophils (16) and correspondingly, we observed a reduction in 
neutrophil Ly6g transcripts. The anti-arthritic actions of 17R-RvD1 were lost in 
Fpr2/3 null mice, reiterating this essential signaling pathway for RvD1 in murine 
inflammation (15, 41). 
 
Once damaged, articular cartilage has limited intrinsic capability to self-repair. 
Importantly, we uncovered unique tissue protective functions of 17R-RvD1 in 
maintaining cartilage integrity during inflammatory arthritis. Chondrocytes were 
identified as target cells for the protective actions of RvD1, stimulating ECM 
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deposition. We provide evidence that 17R-RvD1 protects chondrocytes from IL-1β-
induced degradation via direct ALX/FPR2 receptor ligation. This finding 
complements the array of known functions that pro-resolving mediators exert to repair 
injured tissue in the context of wound healing (42), tissue regeneration (43, 44) and 
restitution of gut epithelial barrier function (45). Our results indicate that mediators of 
resolution could be modeled to repair cartilage if, and when, their receptor target is 
presented on the chondrocyte. Recent work indicate that ALX/FPR2 is expressed by 
human chondrocytes and surface expression is upregulated in catabolic settings, like 
those evoked with IL-1β (21). 
 
The results we present here using synthetic RvD1 as a prototype therapeutic tool from 
the SPM portfolio, a choice dictated by detection of this bioactive mediator in mouse 
and human joints, opens the opportunity to exploit this line of research for innovative 
therapeutic strategies in RA that combine potent anti-inflammatory with tissue-
protective properties. Modeling RvD1 analogues or agonists at its receptor provide 
another avenue for therapeutic development (24). It is important to point out the 
prediction that compared to current therapeutic options; RvD1 and in general SPM-
based therapies will be beneficial in multiple respects. Firstly, SPM do not provoke 
immune suppression (a major side effect associated with biologics e.g. anti-TNF 
therapy (6)) and rather stimulate host phagocyte functions to enhance phagocytosis 
and killing of microorganisms (8, 46, 47). Secondly, SPM exert bone-sparing 
properties (a major secondary effect associated with long-term glucocorticoid therapy 
is bone loss). In the context of experimental periodontitis RvE1 prevents alveolar 
bone loss (48), accelerates bone regeneration (43) and inhibits osteoclast maturation 
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and bone resorption (49). Additionally, parathyroid hormone stimulates RvD1 and 
RvD2 to enhance macrophage efferocytosis of apoptotic osteoblasts highlighting a 
role for SPM in bone homeostasis (50). Thirdly, SPM are potent analgesics (51), and 
relevantly 17R-RvD1 is anti-hyperalgesic in a model of arthritic pain (52). Finally, 
with the present study, we demonstrate novel chondroprotective functions of SPM, 
combating catabolic stimulation and promoting direct anabolic responses enabling 
protection from cartilage degradation during inflammatory arthritis.  
 
In summary, we provide new mechanisms underlying the anti-arthritic properties 
evoked by omega-3 consumption in arthritis (10) and focus on a specific omega-3 
derived SPM, namely RvD1 and its stable epimer 17R-RvD1, to establish proof-of-
concept for the validity of this approach. We defined novel bioactions for this pro-
resolving endogenous lipid mediator in the context of joint inflammation and 
chondroprotection. Together, these results give the foundation for the development of 
innovative therapeutic strategies to avert joint destruction during RA with limited side 
effects, ultimately for the benefit of the patients.   
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Methods:	   
Animals 
Male 12-week old, ~30g, C57Bl/6 (Charles River, Kent) or Fpr2/3 (ALX) null mice 
(generated on a C57Bl/6 background as described (22), and back-backcrossed 10 
times) were maintained on a standard chow pellet diet and had access to water ad 
libitum, with a 12-hour light-dark cycle. For omega-3 diet enrichment studies, mice 
were maintained on a CRM (P) plus 10% salmon oil or standard CRM (P) chow 
(Special diet services, LBS Biotech) 3 weeks prior to and throughout the duration of 
experiments.  
 
Real-time neutrophil chemotaxis using microfluidics chambers  
Microfluidics chambers were engineered for testing the actions of bioactive lipid 
mediators on the chemotactic behaviour of human neutrophils as described previously 
(53). The main channel for assessing neutrophil chemotactic behaviour was modified 
by physical adsorption of P-selectin (50µg/mL, R&D Systems) and ICAM-1 
(10µg/mL, R&D Systems) for 30 mins, followed by blocking with 2% human serum 
albumin (HSA, Sigma-Aldrich) in Hanks' balanced salt buffer (HBSS, Sigma-
Aldrich) immediately before use. Steady-state gradients of IL-8 (0–10nM, R&D 
Systems) were formed in the two gradient generators connected to the main channel, 
one containing vehicle (0.1% ethanol) and the other containing an overlaying uniform 
concentration (1nM) of the specialized pro-resolving lipid mediator for testing 
(Lipoxin A4, B4, Resolvin D1 or D2, Cayman chemicals). Approximately 10µL of 
capillary blood was then collected from healthy volunteers using a BD genie lancet 
(Becton Dickinson), and diluted 1:10 with HBSS, 0.2% HSA. Neutrophils were 
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captured from flowing blood over ∼3 min, and the first valve opened for infusion of 
the IL-8 gradient (fluid flow removed the majority of RBC and other cells that were 
not tethered to the coated chamber) allowing direct monitoring of neutrophils 
captured on the chamber surface. After 15 min, the gradient was switched to the 
second gradient generator containing a uniform concentration of the SPM combined 
with 10nM IL-8 gradient. Neutrophil migration in the chemokine gradient and their 
response(s) to addition of different SPM were recorded every 6 sec, over a 30 min 
period with a digital camera and Image Pro Plus software. Cell migration was 
analyzed using the cell-tracking function in ImageJ software, and tracks analyzed 
utilizing Ibidi Chemotaxis and Migration Tool. Only cells that started and remained 
within the field of view over the entire course of video capture were analysed. At least 
20 cells were tracked per donor, with 3-4 donors per test compound. 
 
K/BxN serum transfer model of inflammatory arthritis  
K/BxN serum was generated in house by breeding NOD/Shiltj mice (Charles River, 
Italy) with KRN transgenic mice (kind gift from Dr. Mohini Gray, Edinburgh 
University, Edinburgh); the subsequent offspring (K/BxN mice) express both the T 
cell receptor (TCR) transgene KRN and the MHC class II molecule Ag7 and 
spontaneously develop a severe inflammatory arthritis. Serum was collected from 
K/BxN mice at 10 weeks of age,	  which	  causes a similar arthritis when transferred to 
recipient mice due to autoantibodies recognizing glucose-6-phosphate isomerase 
(GPI) depositing on the cartilage surface. Serum transfer induced arthritis was 
performed by intraperitoneal injection of 100µl of arthritogenic serum on days 0 and 2 
in WT or ALX/Fpr2/3 null mice. Disease was monitored by assessing the clinical 
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score (maximum 12 points per animal, 3 per limb with the following scoring system 
0, no evidence of inflammation; 1, inflammation in one of the following aspects: 
individual phalanges joints, localized wrist/ankle or swelling on surface of paw; 2, 
inflammation on two aspects of paw; 3, major swelling on all aspects of paw). Paw 
edema was assessed by water displacement plethysmometry (Ugo Basile, Milan, 
Italy). Mice were weighed daily for signs of cachexia. For prophylactic treatment 
regime, WT mice were administered vehicle (0.1% EtOH) or 17R-RvD1 (100ng) in 
100μl of saline i.p. daily (from day 0, 5min prior to arthritogenic serum 
administration). For therapeutic treatment protocol, WT mice were administered 
vehicle (0.1% EtOH) or 17R-RvD1 (100ng) in 100μl of saline i.p. daily following 
overt signs of arthritis (day 4) over a 7 day period. The arthritis remission interval was 
calculated based on arthritic score and calculated by analogy to the resolution indices 
widely used to calculate the loss of neutrophils from an inflammatory site (17, 18). At 
the end of experiments blood was collected via cardiac puncture into heparinized 
syringes, and centrifuged to obtain platelet-free plasma. For intra-articular treatments, 
WT mice were administered K/BxN serum on days 0 and 2 (100µl, i.p.) and were 
treated locally on day 3 with vehicle (left knee, 5µl PBS containing 0.1% EtOH) or 
17R-RvD1 (right knee; 5µl, 100ng 17R-RvD1) and joints were harvested for 
histological analysis on day 5.  
 
Molecular analyses 
Arthritic ankle joints were collected on day 8 and stored in RNAlater at -80°C prior to 
homogenising using Precellys ceramic beads (Bertin Technologies, France). RNA 
was extracted using RNeasy Plus mini kit (Qiagen) and genomic DNA contamination 
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eliminated with Turbo DNA-free kit (Applied Biosystems, USA). Complementary 
DNA was synthesized using SuperScriptIII reverse transcriptase and OligoDt primers 
(Invitrogen). Quantitative real-time PCR was performed using QuantiTect primers 
(Qiagen) and ABI Prism 7900 sequence detector system (Applied Biosystems). 
Relative expression values were calculated following normalization to endogenous 
housekeeping gene Rpl32 and using the 2−(∆∆Ct) method normalized to a naive mouse 
(calibrator sample).  
 
Flow cytometry 
Leukocytes were isolated from arthritic paws following tissue digestion. Briefly, paws 
were collected after 8 days of arthritis, skin carefully removed and digestion buffer 
added (collagenase D (Roche, UK; 0.5μg/ml) and DNAse (Sigma, UK; 40μg/ml) in 
serum free RPMI). Paws were incubated at 37°C with gentle agitation and liberated 
cells collected via a 70μm cell-strainer, and kept on ice. Another 15ml of digestion 
buffer was added to the paws and incubated for a further 30 min. Liberated cells were 
centrifuged at 400g for 10min and re-suspended in PBS for counting. Leukocytes 
were first stained with Zombie NIRTM (Roche, UK; 1:500, 20min, 4°C) to identify live 
cells, and distinct leukocyte subtypes were identified using the following antibodies 
from ebioscience: CD45 (25µg/ml, clone 30-F11), CD11b (0.2µg/ml, clone M1/70), 
Ly6G (25µg/ml, clone RB6-8CS), Ly6C (0.4µg/ml, clone HK1.4) and F4/80 
(10µg/ml, clone BM8). Samples were analysed using an LSR Fortessa flow cytometer 
and FlowJo software (Tree Star Inc.). 
 
Histology 
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Joints were decalcified and paraffin embedded. Sections (8µm) were stained with 
haematoxylin & eosin or 1% aqueous toluidine blue and standard light microscopy 
was used to determine the degree of leukocyte infiltration/synovitis/pannus formation, 
bone erosion and cartilage damage which were each graded from 0 (no disease) to 3 
(severe); max. 9 by two blinded examiners. Cartilage integrity was calculated from 
percentage area of cartilage stained with toluidine blue using thresholds applied with 
ImageJ software. 
 
Determination of plasma KC (CXCL1) levels 
Mice were sacrificed on day 8 following induction of arthritis, blood was collected via 
cardiac puncture into heparinized syringes, and centrifuged to obtain platelet-free 
plasma. KC (CXCL1) values were determined by ELISA.   
 
Targeted LC-MS/MS-based lipidomics of arthritic paws and synovial fluids. 
Paws were collected and immediately transferred to liquid nitrogen prior to 
homogenization in 1ml ice cold MeOH containing deuterated internal standards (d4-
LTB4, d8-5S-HETE, d4-PGE2, d5-LXA4 and d5-LTC4, 500pg each) and homogenized 
using a glass dounce. Synovial fluid (0.5mL) from RA patients (DXBiosamples, city, 
state, country) were placed in 1 mL ice cold MeOH containing deuterated internal 
standards (d4-LTB4, d8-5S-HETE, d4-PGE2, d5-LXA4 and d5-RvD2, 500pg each). All 
samples were kept at -20 oC for 45 min to allow for protein precipitation and 
subjected to solid phase extraction as in (13). Methyl formate fractions were then 
brought to dryness using a TurboVap LP (Biotage) and products suspended in water-
methanol (50:50 vol:vol) for LC-MS-MS. A Shimadzu LC-20AD HPLC and a 
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Shimadzu SIL-20AC autoinjector (Shimadzu, Kyoto, Japan), paired with a QTrap 
6500 (ABSciex, Framingham, MA) was utilized and operated as described (13). To 
monitor each LM and respective pathways, an MRM method was developed with 
diagnostic ion fragments and identification using recently published criteria (13), 
including matching retention time (RT) to synthetic and authentic materials and at 
least six diagnostic ions for each LM. Calibration curves were obtained for each using 
authentic compound mixtures and deuterium labeled LM at 3.12, 6.25, 12.5, 25, 50, 
100, and 200 pg. Linear calibration curves were obtained for each LM, which gave r2 
values of 0.98 – 0.99. 
 
Chondrocyte Micromass Assay  
The human chondrocyte cell line C28/I2 (kind gift from Dr Mary Goldring, Cornell 
Medical College, New York (54)) was utilized for micromass assays as described 
previously (20). Micromasses were stimulated with or without IL-1β (30ng/ml) alone 
or in combination with 17R-RvD1 (0.1-100nM) for 24h and extracellular matrix 
accumulation (ECM) was calculated following staining with Alcian blue as reported 
(21). Briefly, micromasses were fixed (4% glutaraldehyde, 15 min) acidified with HCl 
and stained with Alcian Blue 8GS overnight before dye extraction with guanidine 
hydrochloride (200μl, 6M). Absorbance of extracted dye was measured at 620nm 
using a Multiskan Bichromatic 348 spectrophotometer and normalized to DNA 
content using SYBRgreen dye (excitation 485nm and emission 535nm) with a 
TECAN M200 spectrophotometer (Tecan, Mannedorf, Switzerland). These values 
were used to generate extracellular matrix accumulation concentrations; and are 
expressed as percentage change from control micromasses. In some experiments, the 
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FPR2/ALX receptor antagonist WRW4 (10μM) was added to micromasses 10 min 
prior to 17R-RvD1 addition and ECM accumulation evaluated after 24h. 
 
Statistics 
Statistical analyses were performed with mean ± SEM, where n is the biological 
replicate (individual mice or human donors). Data were analysed using either two-
tailed paired or unpaired Student’s t-test, one-way ANOVA with appropriate post hoc 
analysis, Mann-Whitney t-test or 2-way ANOVA with repeated measures where 
appropriate. Analyses were performed using GraphPad Prism, in all cases, P<0.05 
was considered significant. Multivariate analysis of arthritis metabololipidomics was 
performed using linear discriminant analysis, where bioactive lipid mediator 
predictors were entered simultaneously to the model (carried out in SPSS 23; IBM, 
New York). 
 
Study approval: Human peripheral blood was collected according to a protocol 
approved by Barts and the London Research Ethics Committee, London, United 
Kingdom (QMREC 2014:61), written informed consent was received from 
participants prior to inclusion in the study according to the declaration of Helsinki. All 
animal experiments were approved and performed under the guidelines of the Ethical 
Committee for the Use of Animals, Barts and The London School of Medicine and in 
accordance with the UK Home Office regulations (Guidance on the Operation of 
Animals, Scientific Procedures Act, 1986).  
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Figure 1. Mice fed an omega-3 supplemented diet display reduced arthritis and a 
modulated local biosynthesis of bioactive lipids within arthritic joints. Mice fed a 
standard or omega-3 supplemented diet were given arthritogenic serum (100μl, i.p. on 
days 0 and 2) and (A) arthritic score was evaluated (B) Arthritic paws were collected 
for metabololipidomics analysis on day 8. Linear discriminant analysis was used to 
generate two discriminant functions from the values of bioactive lipid mediators (as 
quantified by LC-MS/MS), which maximize the difference between naïve, arthritis 
and arthritis + omega-3 treatment groups. Each datum corresponds to an individual 
mouse. The model achieves complete discrimination of the three groups. (C) 
Correlations of each lipid mediator with the two linear discriminant functions are 
shown on the bottom x and left y axes. Group centroids for the two discriminant 
functions are plotted on the top x and right y axes to show the directionality and 
association of each lipid with the three treatment groups. n=7-9 mice per group. 
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Figure 2. Identification of Resolvin D1 and D3 in synovial fluids from 
Rheumatoid arthritis (RA) patients. Lipid mediator levels were assessed following 
solid phase extraction by liquid chromatography tandem mass spectrometry (LC-
MS/MS) based metabololipidomics (see methods for details). (A) Representative 
multiple reaction monitoring (MRM) traces for the identified lipid mediators in 
human RA synovial fluids (from n=4). (B) Accompanying MS/MS spectra utilised for 
identification. Refer to Table 2 for patient demographics and Table 3 for 
quantification of bioactive lipid mediators.   
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Figure 3. Direct actions of RvD1, RvD2, LXA4 and LXB4 on human neutrophil 
chemotaxis. Neutrophils were captured from whole blood of healthy volunteers on P-
selectin and ICAM-1-coated microfluidics chambers. Chemotaxis towards an IL-8 
gradient (10nM) was monitored in real-time over 30 min. During the first 15 min cells 
were exposed to HBSS + IL-8 (0-10nM vertical gradient), then cells were exposed to 
a set concentration of resolvin D1 (RvD1), RvD2, lipoxin A4 (LXA4) or LXB4 (1nM) 
or vehicle (HBSS + 0.1% ethanol) together with the IL-8 gradient over the subsequent 
15 min. (A) Representative trajectory paths and (B) rose plots of migrating cells are 
shown. Insets in B show morphology of neutrophils after exposure to IL-8 or pro-
resolving mediators. (C) Quantification of neutrophil chemotaxis index (D) and 
directness of neutrophil migration as depicted by the graphs, n=3-4 donors per 
compound. *P<0.05 **P<0.01 and ***P<0.001 with two-tailed paired Student’s t-
tests. 
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Figure 4. 17R-RvD1 suppresses inflammatory arthritis by limiting leukocyte 
infiltration to arthritic joints. Arthritis was induced with arthritogenic serum 
(100μl, i.p. on days 0 and 2). Mice were treated daily with vehicle (0.1% ethanol) or 
17R-RvD1 (100ng) and (A) arthritic score, (B) paw edema (C) weight loss and (D) 
disease incidence were evaluated. Inset in A are representative photographs of hind 
paw arthritis with and without daily 17R-RvD1 treatment, n=14-17 mice per group. 
***P<0.001 or *P<0.05 two-way ANOVA with repeated measures. (E-G) 
Representative hematoxylin and eosin stained sections of knees from naïve and 
arthritic mice on day 8 after arthritis induction (x4 magnification), from n=5-7 mice 
per group. Scale bars 200µm, F, femur; T, tibia; m, meniscus; IFP, infrapatellar fat 
pad; PF, pannus formation. (H) Histological score calculated by degree of leukocyte 
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infiltration, cartilage and bone erosion, n=5-7 mice per group, *P<0.05 vs. naïve, 
#P<0.05 vs. arthritis, one-way ANOVA with Bonferroni post-hoc test (I) Plasma KC 
levels, n=8-10 mice per group, *P<0.05 one-way ANOVA with Bonferroni post-hoc 
test (J-L) Arthritic paws were digested to liberate leukocytes; cells were counted by 
light microscopy and leukocyte subsets defined using specific antibodies by flow 
cytometry, n=6 mice per group, *P<0.05 unpaired Student’s t-test (M) Mice were 
treated daily following overt signs of arthritis (day 4) for one week with vehicle (0.1% 
ethanol) or 17R-RvD1 (100ng) and arthritic score was evaluated over 32 days and 
arthritis remission indices were calculated n=11-12 mice per group.  
 
  
Norling et al. 
 
 
 
38 
 
 
Figure 5. 17R-RvD1 treatments modulate the local production of bioactive lipid 
mediators within inflamed paws. Arthritic mice were treated daily with vehicle 
(0.1% ethanol) or 17R-RvD1 (100ng) and paws were collected for 
metabololipidomics analysis on day 8, naïve mice were used as controls. (A) Relative 
abundance of key arachidonic acid derived leukotrienes and prostanoids. 
Representative mass spectrum of (B) LTB4 and (C) PGE2 within arthritic paws. (D-T) 
Absolute quantification of lipid mediator levels in arthritic paws identified using 
scheduled multiple reaction monitoring (MRM). n=5-7 per group. *P<0.05 and 
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***P<0.001 vs. naïve and #P<0.05 vs. arthritis with one-way ANOVA and Bonferroni 
post-hoc test.  
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Figure 6. Intra-articular treatment with 17R-RvD1 protects from cartilage 
degradation during inflammatory arthritis. (A) Arthritis was induced with 
arthritogenic serum (100μl, days 0 and 2), mice were treated daily with vehicle (0.1% 
EtOH) or 17R-RvD1 (100ng, i.p.) and paws were collected for gene expression 
analysis on day 8 (see methods), n=8-9 mice per group *P<0.05 with Mann-Whitney 
t-test. (B-C) Mice received arthritogenic serum (100μl, i.p. days 0 and 2), and were 
treated locally on day 3 with vehicle (left knee, 5μl PBS containing 0.1% EtOH) or 
17R-RvD1 (right knee; 5μl, 100ng 17R-RvD1). On day 5, knee joints were collected 
and stained with toluidine blue, n=7 mice per group. Naïve mice were administered 
vehicle or 17R-RvD1 locally and knees collected after 2 days, n=6 mice per group. 
(B) Representative images (x20 magnification) of histological sections from naïve 
and arthritic joints are shown. C, cartilage; m, meniscus. Loss of glycosaminoglycans 
indicated by Δ (C) Cartilage integrity calculated from percentage area of cartilage 
positive for toluidine blue staining, **P<0.01 with two-tailed paired Student’s t-test 
(D-E) In vitro analyses of chondroprotection utilising human C28/I2 micromasses. 
(D) Micromasses were treated with or without IL-1β (30ng/ml) alone or with 17R-
RvD1 (0.1-100nM) and ECM accumulation evaluated (see methods), n=6-10 per 
group, **P<0.01, ***P<0.001 vs. IL-1β with two-way ANOVA and Bonferroni post-
test. Inset representative micromasses stained with Alcian blue prior to dye extraction. 
(E) FPR2/ALX receptor antagonist WRW4 (10μM) was added to micromasses 10min 
prior to 17R-RvD1 and ECM accumulation evaluated after 24h, n=3-7 per group, 
***P<0.001 vs. vehicle, ###P<0.001 vs. respective control with two-way ANOVA and 
Bonferroni post-test. (F) Dependency of Fpr2/3 (ALX) receptor for 17R-RvD1 
protection from inflammatory arthritis. Arthritis was induced in Fpr2/3 (ALX) null 
mice (see methods), mice were treated daily with vehicle (PBS with 0.1% EtOH) or 
17R-RvD1 (100ng, i.p.) and arthritic score assessed, n=9-10 mice per group.  
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Bioactive LM/ 
Pathway Precursors   Lipid mediator levels (pg/paw) 
 
DHA Metabolome 
Q1 Q3 Naïve Arthritis Arthritis  
+ Omega-3 
RvD1 375 215 2.3 ± 1.0 4.0 ± 1.1 6.6 ± 1.4* 
RvD2 375 215  -   -   -  
RvD3 375 181 0.3 ± 0.2 0.4 ± 0.2 1.5 ± 0.9 
RvD5 359 199 9.6 ± 1.3 18.7 ± 2.7** 16.6 ± 1.6* 
RvD6 359 101 2.4 ± 0.7 1.0 ± 0.2 3.1 ± 0.7 
PD1 359 153 2.5 ± 0.5 5.2 ± 1.4 5.0 ± 1.0 
10S,17S-diHDHA 359 153 93.6 ± 16.8 154.5 ± 26.5 123.3 ± 17.7 
MaR1 359 221       3.1 ± 1.3 0.1 ± 0.0* 0.3 ± 0.1 
7S,14S-diHDHA 359 221        3.3 ± 1.1 2.7 ± 0.9 4.2 ± 0.6 
17-HDHA 
14-HDHA 
7-HDHA 
4-HDHA 
343 
343 
343 
343 
245 
205 
141 
101 
313.5 
859.7 
52.9 
109.8 
± 
± 
± 
± 
65.9 
227.3 
8.6 
19.2 
591.1 
1910.4 
49.2 
70.6 
± 
± 
± 
± 
133.3 
331.5 
5.3 
4.4 
1030.9 
2930.1 
156.9 
260.6 
± 
± 
± 
± 
200.4** 
550.1** 
11.1*** 
25.7*** 
 
AA Metabolome      
 
 
 
 
 
 
 
LXA4 351 115        1.3 ± 0.6 4.2 ± 1.5 5.1 ± 2.1 
LXB4 351 221 122.6 ± 65.8 84.2 ± 23.7 199.9 ± 47.9 
5S,15S-diHETE 351 221 3.4 ± 0.4 7.2 ± 1.9 5.0 ± 0.9 
LTB4 335 195 1.8 ± 0.6 4.0 ± 1.4 1.5 ± 0.2 
PGE2 351 189    353.0 ± 156.8 2103.4 ± 229.0*** 628.0 ± 89.8 
PGD2 351 189    155.1 ± 44.5 1246.3 ± 320.1*** 398.4 ± 68.9 
PGF2α 353 193 219.5 ± 97.5 770.9 ± 123.2** 194.8 ± 36.8 
TxB2 369 169 73.0 ± 25.4 254.4 ± 59.2** 73.6 ± 14.3 
5-HETE 
12-HETE 
15-HETE 
319 
319 
319 
219 
179 
115 
632.1 
1453.4 
165.8 
± 
± 
± 
129.6 
381.4 
22.7 
1617.5 
3849.1 
271.2 
± 
± 
± 
508.2 
1041.0 
19.4** 
804.2 
1923.7 
176.9 
± 
± 
± 
228.5 
543.3 
16.6 
EPA Metabolome      
 
 
 
 
 
 
 
RvE1 349 195  -   -   -  
RvE2 333 253 9.7 ± 1.7 6.5 ± 1.4 39.2 ± 5.2*** 
RvE3 333 201   7.1 ± 1.8 4.8 ± 1.4 51.5 ± 16.7** 
18-HEPE 
15-HEPE 
12-HEPE 
5-HEPE 
317 
317 
317 
317 
259 
219 
179 
115 
100.2 
493.5 
228.8 
48.5 
± 
± 
± 
± 
21.9 
97.9 
32.9 
6.5 
42.5 
1589.4 
377.2 
40.2 
± 
± 
± 
± 
3.8 
578.3 
139.0 
3.1 
1213.6 
4470.9 
1583.3 
707.6 
± 
± 
± 
± 
183.2*** 
815.5*** 
298.1*** 
78.8*** 
Table 1. Bioactive SPM and pathway precursors identified in murine naïve and 
arthritic joints. Naïve or arthritic mouse paws were collected for metabololipidomics 
analysis on day 8 (see methods for details). Quantification of bioactive lipid mediators 
(LM) and pathway precursors were assessed by liquid chromatography tandem mass 
spectrometry (LC-MS/MS) based metabololipidomics. Results are expressed as 
pg/paw. Q1: M-H (parent ion) and Q3 (daughter ion): diagnostic ion in the MS-MS. 
Detection limit was ~ 0.1 pg; - denotes below limits. Results are mean ± SEM from 7-
9 mice per group. *P<0.05 **P<0.01 and ***P<0.001 compared to naïve and 
#P<0.05, ##P<0.01 and ###P<0.001 compared to arthritic with one-way ANOVA and 
Tukey’s multiple comparison test.  
### 
### 
### 
### 
## 
## 
# 
### 
## 
## 
### 
###
###
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Diagnosis/ 
Sample type 
Age/ 
Gender Ethnicity 
ACR 
Functional 
Class/Disease 
Activity 
CRP 
(mg/
L) 
RA Medication 
Rheumatoid 
arthritis/ 
Synovial 
fluid 
70/M Caucasian Moderate 20 
Enbrel Sure Stick 50mg/mL 
50mg once a week, 
Celebrex 200mg 2 
times/day, Acetaminophen 
650mg 3 times/day 
Rheumatoid 
arthritis/ 
Synovial 
fluid 
48/F Caucasian Functional Class III 29.6 
Butran 5ug/h 1 patch/wk 
Rituxan 10mg/ml, 1000mg, 
Methotrexate 2.5mg 10 
tabs/wk, Vit D3 1000IU 5 
tabs, Prednisone 7mg/day, 
Folic acid 1 mg/day, 
Pennsaid 1.5% liquid 40 
drops to painful area 4 
times/day as needed, 
Roxicodone 5mg 1-2 tabs 2-
3 times/day 
Rheumatoid 
arthritis/ 
Synovial 
fluid 
40/F Caucasian Functional Class II 17.2 
Humira 40mg SC QWK 
Meloxicam 15mg/day 
Rheumatoid 
arthritis/ 
Synovial 
fluid 
74/F Hispanic Moderate <3 
Leflunomide 10mg/day, 
Aleve 220mg as needed, 
Aspirin 81mg 2 times/day, 
Osteobiflex 1 tab/day 
 
Table 2. Human rheumatoid arthritis patient demographics, disease status and 
medications at the time of sample collection. 
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 Q1 Q3 
 Synovial fluid 
(pg/mL) 
DHA Bioactive Metabolome     
RvD1 375 215                  11.7 ± 2.6 
RvD2 375 215        - 
RvD3 375 215        8.7  ±  3.3 
RvD5 
RvD6 
359 
359 
199 
101 
 
 
- 
-  
       
PD1 359 153   -  
       
MaR1 359 250   -  
       
       
AA Bioactive Metabolome       
LXA4 351 115        - 
LXB4 351 221   -  
5,15-diHETE 335 235                    4.3 ± 1.7 
       
LTB4 335 195                    9.1 ± 3.9 
       
PGE2 351 175                  53.1 ± 23.8 
PGD2 351 189                    4.5 ± 1.3 
PGF2α 353 193                  18.9 ± 5.2 
TxB2 369 169                  14.1 ± 4.1 
       
       
EPA Bioactive Metabolome       
RvE1 349 195         - 
RvE2 333 253         - 
5,15-diHEPE 333 235        2.1  ± 0.7 
       
Table 3. Lipid Mediator-SPM identified in human Rheumatoid arthritis (RA) 
synovial fluid. Quantification of bioactive lipid mediators (LM) in human synovial 
fluid from RA patients assessed by liquid chromatography tandem mass spectrometry 
(LC-MS/MS) based lipid mediator (LM) metabololipidomics. Results are expressed 
as pg/mL synovial fluid. Q1: M-H (parent ion) and Q3 (daughter ion): diagnostic ion 
in the MS-MS. Detection limit was ~ 0.1 pg; - denotes below limits. Results are mean 
± SEM. from 4 donors. 
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Supplemental Data  
 
Supplemental Figure 1. Neutrophil migration trajectories following exposure to 
Specialised pro-resolving lipid mediators (SPM). Neutrophils were captured from 
whole blood of healthy volunteers on P-selectin and ICAM-1-coated microfluidics 
chambers. (A) Neutrophils remained rounded and rapidly detached in the absence of a 
chemotactic gradient. Cells were exposed to media plus vehicle (0.1% ethanol) and 
videos were captured in real-time over 15 min. Representative still images are shown 
for the first 4 min, taken every 6 sec. (B) Rose plots indicating migration trajectories 
from individual donors after exposure to an IL-8 gradient (10nM, 15min) followed by 
exposure to a set concentration of resolvin D1 (RvD1), RvD2, lipoxin A4 (LXA4) or 
LXB4 (1nM, 15min) or vehicle together with the IL-8 gradient.  
 
Vehicle  
no IL-8 gradient  Direction of Fluid Flow 
0 sec 6 sec 12 sec 
1 min 
2 min 
3 min 
18 sec 24 sec 30 sec 36 sec 42 sec 48 sec 54 sec 
A 
Donor 1 Donor 2 Donor 3 Donor 4 
0-
15
 m
in
 Veh  IL-8 
Veh IL-8 
15
-3
0 
m
in
 
Veh IL-8 Donor 1 Donor 2 Donor 3 
LXA4 IL-8 LXB4  
RvD1  RvD2  
B C D 
E F 
Veh IL-8 
IL-8 
Donor 1 Donor 2 Donor 3 
Direction of Fluid Flow 
Veh  IL-8 
IL-8 
Donor 1 Donor 2 Donor 3 Donor 4 
0-
15
 m
in
 
15
-3
0 
m
in
 
Donor 1 Donor 2 Donor 3 Donor 4 Veh  IL-8 
IL-8 
Norling et al. 
 
 
 
45 
 
 
Supplemental Figure 2. Histopathology of murine knee joints is improved with 
17R-RvD1 treatment. (A) Representative haematoxylin & eosin histology sections 
of knee joints from arthritic mice 8 days after arthritis induction following daily 
administration of vehicle (0.1% ethanol in PBS, i.p.) or (B) 17R-RvD1 (100ng, i.p.). 
Representative low (x4) and high (x20) power magnifications are shown for each 
genotype. F; femur, T; tibia, m; meniscus, PF; pannus formation, BE; bone erosion, S; 
synovitis, *; neutrophil infiltration, from n=5-7 mice per group.  
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Supplemental Figure 3. Joint protection from 17R-RvD1 is lost in Fpr2/3 (ALX) 
null mice. (A) Representative haematoxylin & eosin histology sections of murine 
arthritic hind paws 8 days after arthritis induction (x10 magnification). (B) 
Histological score calculated by degree of leukocyte infiltration (max. 3), n=5-6 mice 
per group. 
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Relative Expression (AU) 
 
 
Gene Arthritis Arthritis  + 17R-RvD1 % Change 
 
Alox15 
 
1.76 
 
± 
 
0.73 
 
3.74 
 
± 
 
1.12 + 112.5 
Il-1β  22.56 ± 9.96 10.57 ± 2.58 - 53.2 
Ly6g 4.85 ± 2.66 1.31 ± 0.35 - 73.0 
Ptsg2 
 
21.05 
 
± 
 
10.78 
 
6.35 
 
± 
 
2.06 
 
- 69.9 
        
Supplemental Table 1. Comparative relative expression of inflammatory genes in 
murine arthritic joint tissue.  Arthritic mouse paws were collected for gene analysis 
on day 8 (see methods for details). Relative expression values were calculated 
following normalization to endogenous housekeeping gene Rpl32 and using the 
2−(∆∆Ct) method normalized to a naïve mouse (calibrator sample).  
 
 
 
